COMMUNIQUÉS West-GlobeNewswire

PacBio HiFi Technology Selected as Core Platform for South Korea’s National Pangenome Project
13/10/2025
More than 1,000 Korean genomes to be sequenced for global reference standards, advancing disease research and precision medicine MENLO PARK, Calif. and SEOUL, South Korea, Oct. 13, 2025 (GLOBE NEWSWIRE) -- PacBio ( [...]
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
13/10/2025
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the [...]
General Oncology to Present Preliminary Phase 1 Results from SHARON Trial in Patients with BRCA/PALB2-mutated Pancreatic and Breast Cancer at ESMO 2025
13/10/2025
BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- General Oncology, Inc. (“General Oncology” or the “Company”), a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for metastatic cancers [...]
New Study Confirms Stress-Reduction Benefits of Natural Remedies’ Ashwa.30
13/10/2025
BANGALORE, India, Oct. 13, 2025 (GLOBE NEWSWIRE) -- A new study conducted by Clinical Research Australia reinforces the stress-reducing potential of Natural Remedies ’ Ashwa.30 , a next-generation ashwagandha extract. [...]
EarlyHealth Group acquiert CYB3R, l’entreprise de cybersécurité à la croissance la plus rapide du Golfe
13/10/2025
DUBAÏ, Émirats arabes unis, 13 oct. 2025 (GLOBE NEWSWIRE) -- EarlyHealth Group, une société internationale du secteur des services pharmaceutiques et des solutions pour les sciences de la vie, a acquis une participation [...]
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
13/10/2025
- Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET - Poster presentation on preclinical evaluation of petosemtamab on cancer stem cells: Friday, October 24 12:30-4:00 p.m. ET UTRECHT, The [...]
Quanta Therapeutics Announces First Clinical Data Presentation for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
13/10/2025
RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company leading the development of innovative, oral therapeutics for [...]
Press release: Transparency Notification from Shareholder
13/10/2025
Transparency Notification from Shareholder Ghent, Belgium – 13 October 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of drug-resistant fluid [...]
Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium
13/10/2025
Groundbreaking oncology development with the first dual payload peptide drug conjugate platform, establishing Avacta as a leader in combination therapy innovation LONDON and PHILADELPHIA, Oct. 13, 2025 (GLOBE NEWSWIRE [...]
Artios to Announce First Phase 1/2a Data for DNA Polymerase Theta (Polθ) Inhibitor ART6043 in Advanced Solid Tumors in Oral Presentation at ESMO
13/10/2025
CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage response (“DDR”) in [...]
Together We Build: Rentschler Biopharma celebrates construction progress of new buffer media facility, largest single investment at Laupheim site
13/10/2025
Symbolic milestone for new buffer media station: Rentschler Biopharma underscores its commitment to the Laupheim headquarters and to the future of Germany and Europe as leading biotechnology hubs Shaping dialogue: Panel [...]
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation
13/10/2025
NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) , a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medicines in [...]
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
13/10/2025
FRIENDSWOOD, Texas, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its [...]
Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events
13/10/2025
CHASKA, Minn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company [...]
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
13/10/2025
– Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that new [...]
Kraig Biocraft Laboratories Announces Selective Breeding Advancement, Significantly Increasing Both Spider Silk Production Throughput and Hybrid Vigor
13/10/2025
ANN ARBOR, Mich., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company", “Kraig” or "Kraig Labs"), a world leader in spider silk technology*, is proud to announce the Company has [...]
Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program
13/10/2025
RDEA Pilot Program provides sponsors enhanced communication and collaboration with FDA to accelerate development of rare disease therapies CLEVELAND, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: [...]
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
13/10/2025
Second year proceeds granted following FDA review of annual performance progress report on Phase 3 SELVA single-arm, baseline-controlled trial; up to $2.6 million in non-dilutive funding anticipated over the grant [...]
BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025
13/10/2025
Biomarkers identified in Phase 2 study demonstrate similar trends in ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast cancer (MBC) Positive delayed-type hypersensitivity (DTH) – a potential biomarker [...]

Pages